Jasper Therapeutics Stock (NASDAQ:JSPR)

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for hematopoietic stem cell transplantation and gene therapies. Its core mission is to develop and commercialize conditioning agents and advanced stem cell engineering methods. These advancements aim to expand the utility of stem cell transplantation and ex vivo gene therapy, a process involving genetic modification of cells outside the body before their transplantation. JSP191 stands as the company's leading investigational product, currently in clinical development. This conditioning antibody functions by ablating hematopoietic stem cells from patients' bone marrow as a prerequisite for allogeneic stem cell or stem cell gene therapy. Additionally, Jasper is creating engineered hematopoietic stem cell product candidates intended to address significant limitations inherent in both allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.